tert-Butyl 2-(6-chloropyridin-2-yl)acetate

Catalog No.: 
ACRNZV315
CAS No.: 
1104643-30-2
Molecular Formula: 
C11H14ClNO2
Molecular Weight: 
227.69
tert-Butyl 2-(6-chloropyridin-2-yl)acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$178.00InquiryInquiry
250mg95%$325.00InquiryInquiry
1g95%$813.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 2-(6-chloropyridin-2-yl)acetate
IUPAC Nametert-butyl 2-(6-chloropyridin-2-yl)acetate
Molecular FormulaC11H14ClNO2
Molecular Weight227.69
SMILESO=C(OC(C)(C)C)CC1=NC(Cl)=CC=C1
InChI KeyMXZUYXCASZLGOQ-UHFFFAOYSA-N
Synonymtert-Butyl 2-(6-chloropyridin-2-yl)acetate
CAS No.1104643-30-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACRNZV315 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBOTL036 route compound structure diagram
    ACBOTL0365140-72-7In Stock
  4. Then
  5. ACRNZV315 route product structure diagram
    ACRNZV3151104643-30-2
Inquiry

2. ACRNZV315 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACGRNK947 route compound structure diagram
    ACGRNK947885267-14-1In Stock
  4. Then
  5. ACRNZV315 route product structure diagram
    ACRNZV3151104643-30-2
Inquiry

3. ACRNZV315 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRNZV315 route product structure diagram
    ACRNZV3151104643-30-2
Inquiry

Comments (0)